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Abstract: Colorectal cancer (CRC) is the second most common cause of cancer-related death in Europe and its prognosis 
is largely dependent on stage at diagnosis. Currently, there are no suitable tumour markers for early detection of CRC. In a 
retrospective study we previously found discriminative CRC serum protein proﬁ  les with surface enhanced laser desorption 
ionisation—time of ﬂ  ight mass spectrometry (SELDI-TOF MS). We now aimed at prospective validation of these proﬁ  les. 
Additionally, we assessed their applicability for follow-up after surgery and investigated tissue protein proﬁ  les of patients 
with CRC and adenomatous polyps (AP). Serum and tissue samples were collected from patients without known malignancy 
with an indication for colonoscopy and patients with AP and CRC during colonoscopy. Serum samples of controls (CON; 
n = 359), patients with AP (n = 177) and CRC (n = 73), as well as tissue samples from AP (n = 52) and CRC (n = 47) were 
analysed as described previously. Peak intensities were compared by non-parametric testing. Discriminative power of dif-
ferentially expressed proteins was assessed with support vector machines (SVM). We conﬁ  rmed the decreased serum levels 
of apolipoprotein C-1 in CRC in the current population. No differences were observed between CON and AP. Apolipopro-
tein C-I levels did not change signiﬁ  cantly within 1 month post-surgery, although a gradual return to normal levels was 
observed. Several proteins differed between AP and CRC tissue, among which a peak with similar mass as apolipoprotein 
C-1. This peak was increased in CRC compared to AP. Although we prospectively validated the serum decrease of apoli-
poprotein C-1 in CRC, serum protein proﬁ  les did not yield SVM classiﬁ  ers with suitable sensitivity and speciﬁ  city for 
classiﬁ  cation of our patient groups.
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Introduction
Colorectal cancer (CRC) accounts for about 10% of cancer deaths annually and is thereby is the second 
most common cause of cancer-related death in both men and women in Europe (1). Upon diagnosis, 
most patients already have developed locally advanced or metastasised disease. More will develop 
metastasis during follow-up. Though, when diagnosed and treated early, the overall 5-year survival rate 
is around 90%. Unfortunately, there are currently no suitable tumour markers for early diagnosis of 
CRC. Non-invasive diagnostic methods that could be suitable for screening patients, such as measure-
ment of serum carcinoembryonic antigen (CEA) levels, faecal occult blood testing and faecal DNA 
analysis, all have low sensitivities and/or speciﬁ  cities (2–5).
Recently developed technologies like genomic and proteomic proﬁ  ling provide new opportunities 
to search for diagnostic biomarkers. Microarray analyses have yielded highly predictive prognostic 
proﬁ  les for e.g. breast cancer (6). However, genomic analyses depend on the availability of tissue mate-
rial to assess acquired genetic changes and are thus less suitable for screening large populations or 
follow-up of patients after surgery. In contrast, proteomic proﬁ  ling can be done in easily-accessible 376
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body ﬂ  uids like serum, which can be assessed 
before, during and after (treatment for) CRC. As 
tissue is constantly perfused by the blood, (tumour) 
tissue-originating proteins, but also tissue-
processed endogenous proteins are represented in 
the blood and can reﬂ  ect the actual state of an 
individual’s health.
Several techniques can be used for protein 
proﬁ  ling (for an overview see e.g. (7)). To assess 
large sample groups, a high throughput method 
that does not need much pre-analytical sample 
clean-up is preferable. We and others have 
previously searched for CRC serum protein 
proﬁ  les with surface-enhanced laser desorption 
ionisation-time of flight mass spectrometry 
(SELDI-TOF MS) (8–13). Although much debate 
has surrounded this technology, several 
discriminating proteins in these studies overlapped, 
indicating inter-laboratory reproducibility and 
validity. However, in these studies most CRC 
patients had advanced disease and were compared 
to healthy controls. As the ultimate goal is to use 
protein proﬁ  ling for early diagnosis, possibly even 
in pre-cancerous stages, prospective studies are 
needed in a more heterogeneous population of 
patients at risk. Furthermore, for protein proﬁ  les 
to be suitable for follow-up of CRC patients, their 
levels should be reﬂ  ective of response to treatment 
or relapse.
Comparison of tissue protein proﬁ  les can give 
more insight into the pathophysiological mecha-
nisms underlying or accompanying CRC. Addi-
tionally, comparing tissue protein profiles of 
different stages along the so-called adenoma-
carcinoma sequence can provide knowledge on the 
extent of transformation that has occurred in the 
different histologic subtypes of polyps.
In the current study we aimed to prospectively 
validate our previous CRC serum protein proﬁ  les 
with SELDI-TOF MS in a new population of 
patients with an indication for colonoscopy. After 
colonoscopy patients were attributed to a control 
group, a group with adenomatous polyps or a group 
with colorectal cancer. Serum protein proﬁ  les of 
these groups were compared for discriminating 
proteins. Additionally, serum protein proﬁ  les of 
patients with colorectal cancer at baseline were 
compared to those more than 3 weeks after surgi-
cal resection of the tumour. Lastly, tissue protein 
proﬁ  les were acquired from polyp and CRC tissues 
and compared.
Materials and Methods
Patients and samples
Patients above 18 years old with no history of 
malignancies (curatively treated melanoma and 
cervix carcinoma excluded) presenting with an 
indication for colonoscopy at the department of 
Gastroenterology and Hepatology or presenting 
for treatment of a colorectal tumour were asked 
for participation in this study. Patients were 
included in two hospitals: The Slotervaart 
Hospital or the Netherlands Cancer Institute/
Antoni van Leeuwenhoek Hospital (both in 
Amsterdam, The Netherlands). The study was 
approved by the local medical ethics committees 
of both institutes and informed consent of every 
patient was obtained.
A serum sample was collected from each par-
ticipant either before colonoscopy or, when appli-
cable, before treatment of a colorectal tumour 
(Fig. 1). Following colonoscopy, diagnosis was 
recorded for each individual. Three groups were 
deﬁ  ned: control (CON), adenomatous polyps (AP) 
and colorectal cancer (CRC). A second serum 
sample was collected from CRC patients at least 
3 weeks after surgery if no adjuvant chemotherapy 
was given. Serum collection was done following 
Serum
sample
Colonoscopy
CON
AP
CRC
Removal at
colonoscopy
Tissue
sample
Tissue
sample
Surgery  
Treatment Diagnosis Inclusion Follow-up > 3 weeks
post-surgery
Serum
sample
Figure 1. Study set-up.377
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a strict protocol in which samples were collected 
in 9.5-ml BD Vacutainer
® SST™ tubes (Becton 
Dickinson, Breda, The Netherlands) and allowed 
to clot for exactly 30 min at room temperature, 
after which they were centrifuged at 1500 g for 
15 min at room temperature. Samples were then 
immediately aliquotted and stored at −70 °C.
Tissue samples were collected from patients 
with adenomatous polyps 0.5 cm or CRC. Tissue 
was collected dry and tissue sections snap frozen 
in liquid nitrogen immediately after collection at 
the department of Pathology. Tissues were stored 
in liquid nitrogen until analysis.
Preparation of tissue lysates
Snap frozen tissue sections were disintegrated in 
deep frozen state by pulverisation with a Micro-
dismembranator II (Sartorius AG, Göttingen, 
Germany) (14). First, tissues were cut into smaller 
blocks, placed into a pre-cooled shaking ﬂ  ask with 
a stainless steel ball and then pulverised in three 
rounds of shaking (55s) and cooling in liquid 
nitrogen (3 min). Ten mg of the resulting frozen 
tissue powder was then added to 100 μl of dena-
turation buffer consisting of 9 M urea, 2% 3-
[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonate (CHAPS) and 1% dithiotreitol 
(DTT) and stored at −70 °C until analysis. For mea-
surement of the protein concentration lysates were 
thawed on ice, centrifuged at 15000 rpm for 5 min 
and the supernatant collected for protein proﬁ  ling. 
Protein concentration in the supernatants was 
determined using the 2D-Quant Kit (GE Health-
care, Diegem, Belgium) according to the manufac-
turer’s instructions.
Protein proﬁ  ling
All serum samples were analysed with SELDI-
TOF MS (Biorad Laboratories, Hercules, CA, 
U.S.A.) on CM10 chips as described previously 
(10). Sample processing was manual, therefore, all 
samples were randomly attributed to one of nine 
measurement series before analysis and each series 
was measured in duplicate on one day. Sample 
allocation to the chips was randomised, but dupli-
cates were spotted on different chips to take into 
account inter-chip variability. Pre- and post-surgery 
sera of CRC patients were assessed similarly in a 
separate analysis. Tissue lysates were also analysed 
in duplicate in a separate series using the same 
procedures as for serum. The amount of lysate 
applied to the chips was adjusted to the protein 
concentration in each sample.
Protein chips were read using the PBS-IIC 
ProteinChip Reader (Biorad Laboratories). Data 
were collected between 0 and 200 kDa. An average 
of 105 laser shots per spectrum at laser intensity 
140 and detector sensitivity 6 was collected. The 
focus mass was set to 3000 Da. Settings for tissue 
analysis were optimised independently, resulting 
in an average of 105 laser shots per spectrum at 
intensity 165 and detector sensitivity 6 and a focus 
mass at 6000 Da. Mass-to-charge (m/z) values were 
calibrated externally with the all-in-one peptide 
mixture (Biorad Laboratories).
Statistics and Bioinformatics
Raw data from all acquired spectra was exported 
from the Ciphergen ProteinChip Software (Biorad 
Laboratories) after baseline correction. 
Normalisation, peak detection and peak clustering 
were performed using the MASDA R-package 
(http://bioinformatics.nki.nl). Individual spectra 
were normalised by centring around zero and divid-
ing by the standard deviation. Peak detection and 
clustering was performed within a maximum win-
dow of 0.3% of the current m/z. All duplicate 
measurements were averaged and group differ-
ences between CON, AP and CRC serum or tissue 
and between pre- and post-surgery sera were 
assessed with non-parametric statistical tests cor-
rected for multiple testing using the Benjamini-
Hochberg correction. A p-value 0.01 was deﬁ  ned 
as a statistically signiﬁ  cant difference.
Classiﬁ  cation models in the form of Support 
Vector Machines (SVM) were built for each pair 
wise combination of classes, i.e. CON vs. CRC, 
CON vs. AP and AP vs. CRC. A radial basis kernel 
was used for its generally good performance. 
A double-loop 10-fold cross-validation procedure 
was used to estimate parameters and to assess 
model performance (15). Optimisation of the cost 
parameter C and kernel parameter γ was done 
within the inner loop, whereas the outer loop was 
used to estimate the performance of a chosen model 
on an independent test set. To take into account the 
large prior probability of being classiﬁ  ed as CON 
due to the much larger sample size of this group, 
performance was estimated using the mean ratio 
of the true positive and true negative rate. The 
R-packages e1071 and svmpath were used in the 
model building process. All other statistical 378
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analyses were performed with SPSS version 15.0 
(SPSS Inc. Chicago, IL, U.S.A.).
Results
Patients and samples
In total, 731 patients with an indication for colo-
noscopy were asked for participation in this study 
(Table 1). One hundred and twenty-two patients 
had to be excluded from serum sample analysis: 
41 were found ineligible according to the inclu-
sion criteria, 21 did not give informed consent, 
47 did not provide a serum sample for analysis 
and 13 did not show up for colonoscopy. The 
total number of patients evaluable for serum 
protein proﬁ  ling was 609. The patients excluded 
for serum analyses did not signiﬁ  cantly differ in 
gender, but were older (64.8 vs. 59.6 years, 
p = 0.01) and had slightly different indications 
for colonoscopy and diagnoses compared to 
evaluable patients. They comprised fewer 
patients with rectal blood loss (5.9 vs. 13.4%) 
and more patients with changes in defecation 
(22.8 vs. 17.0%). Also diagnoses were somewhat 
different for the excluded patients. There were 
fewer patients with AP (17.9 vs. 29.0%) and more 
patients with CRC (18.8 vs. 12.0%) in this group 
compared to the evaluable patients. Tissue was 
obtained from 118 individuals, of which 54 CRC. 
The characteristics of all assessable patients are 
described in Tables 2 and 3.
CON, AP and CRC serum protein 
proﬁ  les
We detected 28 significantly different peaks 
between CON, AP and CRC (Table 4). Most peaks 
differing between CON and CRC were also sig-
nificantly different between AP and CRC. No 
signiﬁ  cant differences were observed between 
CON and AP. Several of the signiﬁ  cantly different 
peaks corresponded to the masses of apolipoprotein 
C-I and its fragment without the N-terminal threo-
nine and proline (6.6 and 6.4 kDa; doubly charged 
molecules: 3.3 and 3.2 kDa). Previously identiﬁ  ed 
biomarker candidates at 3.1 and 28 kDa were not 
detected in the current analyses, and for m/z 4.5 
no expression difference was observed. No cor-
relation with age or polyp size was observed for 
any of the discriminating peaks. All detected peaks 
were used for model-building with SVM. However, 
no suitable model was obtained for the discrimina-
tion of CON, AP and CRC. The mean 10-fold 
cross-validation performances of the SVM classi-
ﬁ  ers for comparison of CON vs. CRC, CON vs. 
AP and AP vs. CRC were 57.7%, 59.4% and 50.1% 
respectively.
Table 1. Indications for colonoscopy of patients asked for participation in this study.
Indication for colonoscopy N = 731 (100%)
Rectal blood loss 98 (13.4%)
Abdominal discomfort 101 (13.8%)
Anaemia 34 (4.7%)
Family history of AP or CRC 136 (18.6%)
Follow-up after previous AP 96 (13.1%)
Altered bowel habits/movements 124 (17.0%)
Family history of AP or CRC and 
abdominal discomfort
23 (3.1%)
Family history of AP or CRC and rectal 
blood loss
14 (1.9%)
Suspected malignancy (signs of bowel 
obstruction, suspect lesion by imaging)
21 (2.9%)
FAP gene mutation carrier 3 (0.4%)
At risk for HNPCC 33 (4.5%)
Conﬁ  rmed HNPCC mutation carrier 12 (1.6%)
Other/unknown 36 (4.9%)379
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Pre- and post surgery serum protein 
proﬁ  les
Pre- and post-surgery serum samples were available 
from 24 CRC patients (marked in Table 3). Post-
surgery samples were drawn 26−201 days after 
surgery. No signiﬁ  cant differences were observed 
between the pre- and post-surgery serum protein 
proﬁ  les. Sixteen of 24 patients demonstrated an 
increase for m/z 3315 post-surgery, as well as 14 
patients for m/z 6628. Post-surgery peak intensities 
for these peaks correlated with the time between 
surgery and the collection of the post-surgery 
serum sample (r = 0.4, p  0.05).
CON, AP and CRC tissue protein 
proﬁ  les
From 103 patients tissue protein proﬁ  les were 
evaluable (Table 2b). Tissues were classified 
according to their histology as CON (hyperplastic 
polyps, AP0), AP (tubular and tubulovillous pol-
yps; AP1 and AP2 respectively) and CRC (tumour 
tissue and polyps with carcinoma in situ (AP3)). 
We found 31 peaks that were signiﬁ  cantly different 
between tissues (Table 5), many of which showed 
a gradual increase or decrease going from CON to 
AP to CRC (Fig. 2A). Peaks with m/z 6.6 kDa were 
found that were increased in CRC compared to AP 
and CON and also across the different subtypes of 
polyps (Fig. 2B). E.g., for m/z 6640 the peak inten-
sities of polyps with carcinoma in situ largely 
overlapped with those for CRC tissue (compare 
Fig. 2A and B), whereas peak intensities in tubular 
polyps (AP1) are closer to those of hyperplastic 
polyps (AP0). However, we were unable to classify 
patients with sufﬁ  ciently good sensitivity and 
speciﬁ  city based on these tissue protein proﬁ  les. 
Examples of tissue spectra are shown in Figure 3. 
Table 2a. Characteristics of diagnostic groups evaluable for serum protein proﬁ  ling.
CON (n = 359) AP (n = 177) CRC (n = 73)
Male sex 163 (45.4%) 89 (50.3%) 43 (58.9%)
Mean age (years ± SD) 57.4 ± 13.0 61.0 ± 12.1 67.8 ± 12.0
1
Polyp histology
 Hyperplastic 65
 Tubular 120
 Tubulovillous 57
  Carcinoma in situ 12
Mean polyp size (mm ± SD) 4 ± 28  ± 6 17 ± 6
1
Median CEA (μg/l) [range] N.A. N.A. 4.10 [0.2–1338]
1p  0.001; CON vs. AP vs. CRC.
N.A. not assessed.
Table 2b. Characteristics of diagnostic groups evaluable for tissue protein proﬁ  ling.
CON (n = 4) AP (n = 52) CRC (n = 47)
Male sex 3 (75%) 25 (48.1%) 25 (53.2%)
Mean age (years ± SD) 58.2 ± 8.43 60.4 ± 11.7 67.3 ± 11.9
1
Polyp histology
 Hyperplastic 4
 Tubular 12
 Tubulovillous 39
  Carcinoma in situ 12
Mean polyp size (mm ± SD) 10 ± 4 15 ± 6 17 ± 8
1p = 0.012; CON vs. AP vs. CRC.380
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Table 3. Tumour characteristics of evaluable CRC patients.
Patient ID no pT pN pM Tumour location Patient ID no pT pN pM Tumour location
05070535
1 1 0 0 Sigmoid 06070187 3 0 0 Sigmoid
05070478
2 0 X 07020087
1 2 1 X Colon ascendens
05100137
1 2 0 0 Sigmoid 06050316 3 1 X Rectum
06030371 X X 1 Rectum 06110117 3 1 0 Colon ascendens
06030418
1 2 0 0 Rectum 06110151
1 2 2 X Rectum
06050222 3 0 0 Rectum 07010024 3 1 X Rectum
06080016
1 4 2 1 Sigmoid 07020119
1 2 0 X Rectosigmoid
06090095
1 2 0 X Sigmoid 06020194 3 1 1 Coecum/colon 
ascendens
06090301
2 0 X X Rectum 06040207
1 3 1 X Coecum
06110347 2 0 X Rectum 06050009 3 0 X Colon
06120034 . . . Rectum 06050178
1 3 1 X Sigmoid
05100238
2 0 X X Sigmoid 06070077 X X 1 Rectum
06020328
2 0 X X Sigmoid 06070325 3 0 0 Rectum
06030153
1 3 0 0 Colon transversum 06120047 4 1 X Coecum/colon 
ascendens
06030315 2 1 X Rectum 07030059 . . . Rectum
06050013 3 0 0 Coecum 07030137
2 0 X X Rectum
06070009
1 3 0 X Colon ascendens 07030258 3 0 X Colon ascendens
06070335 3 1 X Flexura hepatica 07060033 3 0 X Colon transversum
06070336 3 0 X Rectum 07060197 2 1 X Sigmoid
06090220 3 1 0 Flexura hepatica 05100138
1 3 0 0 Rectosigmoid
06120213 3 1 X Sigmoid 06070178 X X 1 Rectum
07010234 X X 1 Sigmoid 06100105 2 1 X Rectum
07010316 3 1 X Sigmoid 06100115
1 3 0 1 Rectum
05120313
1,2 1 0 X Rectum 07040138 2 0 X Rectum
05080096
1 3 0 0 Colon transversum 07050173
1 3 0 X Sigmoid
06020162
2 1 X X Sigmoid 07060014 3 0 X Colon
06030355
2 1 X X Sigmoid 07060037 3 . . Rectum
06060392 3 1 X Sigmoïd 07060149 2 X X Sigmoid
06070073
1 3 0 X Coecum 07060162 2 0 0 Rectum
07010397
1 3 2 X Rectum 06060102
1 3 0 X Sigmoid
05090276
1 X 0 X Rectum 06080189 4 1 1 Appendix
06010268
2 0 X X Sigmoid 07060161 3 0 X Rectum
06020195
1 3 0 0 Coecum 07070078 3 1 X Rectum
06020339
2 0 X X Rectum 07070079 2 . X Rectum
06040166
1 3 0 0 Colon ascendens 06110038
2 0 X X Rectosigmoid
06040213
1 4 0 0 Sigmoid 07020194
2 0XX
pT, pN, pM: pathologically determined tumour stage according to the TNM system.
1Also used in pre- vs. post-surgery comparison.
2Carcinoma in situ.381
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A correlation with polyp size was observed for 
peaks 6640 (r = 0.369; p = 0.003), 6713 (r = 0.419; 
p = 0.001), 11517 (r = 0.382; p = 0.002) and 12705 
Da (r = −0.390; p = 0.002).
Discussion
In the current study we prospectively validated our 
previous serum protein proﬁ  les in CRC patients 
with advanced disease in a new population of 
patients with mostly early-stage CRC, adenomatous 
polyps and controls with an indication for colonos-
copy. To our knowledge, this is the ﬁ  rst large-scale 
clinical study in which previously established CRC 
serum protein proﬁ  les are validated in a clinically 
relevant population of patients with an indication 
for colonoscopy. Of the 690 eligible patients who 
were asked to participate in this study, 609 were 
evaluable for serum analysis (88.3%). Small dif-
ferences between the evaluable and non-evaluable 
patients were the older age of the latter group and 
Table 4. Signiﬁ  cantly different peaks in serum protein 
proﬁ  les. (No signiﬁ  cant differences between CON and 
AP were observed.)
M/z (Da) Multiple testing-corrected p-values
CON vs.
AP vs. CRC
CON vs.
CRC
AP vs.
CRC
3215 0.01 0.002 0.001
3314 0.0058 0.002 0.001
3315 0.0045 0.007 0.002
4279 NS 0.002 0.009
4625 NS 0.007 0.001
6427 NS 0.002 0.002
6428 NS 0.002 0.002
6625 0.0039 0.004 0.001
6626 0.0039 0.005 0.002
6634 0.0063 0.006 0.002
7559 NS NS 0.004
11615 NS 0.007 0.007
11649 0.004 0.004 0.001
11669 NS NS 0.001
13241 NS NS 0.009
15091 NS NS 0.001
15102 0.005 0.007 0.001
15114 0.005 0.004 0.001
15142 NS 0.007 0.001
15202 NS NS 0.001
15303 0.007 NS 0.001
15327 NS NS 0.001
18582 NS 0.008 NS
66202 NS 0.007 NS
66328 NS 0.007 NS
66426 NS 0.007 NS
66520 NS 0.008 NS
NS: not signiﬁ  cant.
Table 5. Signiﬁ  cantly different peaks in tissue protein 
proﬁ  les. (No signiﬁ  cant differences between CON and 
AP or between CON and CRC were observed.)
M/z (Da) Multiple testing corrected
p-values
CON vs.
AP vs. CRC
AP vs. CRC
3249 0.001 0.001
3351 0.010 0.014
3442 0.001 0.001
4477 0.005 0.010
4903 0.012 0.004
5358 NS 0.010
6622 0.002 0.001
6640 0.004 0.005
6713 0.004 0.006
7669 0.006 0.002
7955 0.001 0.001
8568 NS 0.005
8854 0.001 0.001
9246 0.001 0.001
10435 0.001 0.001
11517 0.003 0.005
11649 NS 0.006
12705 NS 0.006
13157 0.002 0.001
15307 0.005 0.002
16022 NS 0.006
26150 0.005 0.004
31090 0.005 0.002
31922 0.001 0.001
41879 0.006 0.002
NS: not signiﬁ  cant.382
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Figure 2. Tissue protein peak intensities in A) CON, AP and CRC and B) AP0, AP1, AP2, AP3.383
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different indications and diagnoses for colonoscopy. 
Comparison of latter indicates that patients with the 
least and most severe diagnosis were most likely 
to be non-evaluable. That is, patients whose com-
plaints disappeared were more likely to miss colo-
noscopy, whereas patients with CRC were more 
likely to give no consent because of their disease. 
The omission of these extremes in the eligible 
population may have precluded the detection of 
more differences between patients and controls. We 
conﬁ  rmed the decreased expression of m/z 3.3 and 
6.6 kDa, two ions of apolipoprotein C-I, in the 
current population of CRC patients. Recently we 
have shown that one of our earlier biomarker 
candidates, an N-terminal albumin fragment of 
3.1 kDa, is a product of proteolysis during storage 
at −20 °C (16), explaining why we did not observe 
this peak in this analysis. The lack of an expression 
difference for peaks at 4472 Da and 28 kDa is likely 
related to the different patient characteristics or 
sample handling protocol compared to our previous 
study. We did not ﬁ  nd any signiﬁ  cant differences 
between pre- and post-surgery serum protein 
profiles. As apolipoprotein C-I is synthesised 
mainly by the liver and small intestine (17), it is 
plausible that resection of the tumour does not 
immediately influence the abundance of this 
protein. However, we observed a correlation 
between the post-surgery peak intensities of m/z 3.3 
and 6.6 kDa and the time between surgery and 
serum collection, indicating that apolipoprotein 
C-I levels do return to normal, but with a time-lag 
of about 3 months after surgery (data not shown). 
Also for CEA a time lag of 6 to 12 weeks levels 
after surgery is common before levels return to 
normal.
Although we validated the serum decrease of 
apolipoprotein C-I in this group of patients with 
early-stage CRC, we could not use the acquired 
serum or tissue protein proﬁ  les as such for correct 
classiﬁ  cation of CON, AP and CRC. We expected 
that the potential to classify patients by their serum 
protein profile would be lower in the current 
population, since we compared patients with early-
stage disease to a control group which was essen-
tially not ‘healthy’. Because of this, more 
background noise was introduced in this analysis. 
However, an analysis in this population is essential 
for assessment of the clinical utility of this type of 
mass spectrometric profiling. Importantly, we 
could not discern patients with AP from CON, 
which would be advantageous in establishing 
which patients need a colonoscopy for removal of 
AP. Quantitative methods are needed to determine 
the actual differences in serum levels of apolipo-
protein C-I between CON, AP and CRC. Then, 
suitable cut-off levels can be established for clini-
cal use. Such an approach was taken e.g. by 
Habermann et al., who used an ELISA for quanti-
tation of complement C3a des-Arg and validated 
their MS results (13). Although others have sug-
gested serum protein proﬁ  les on a different chip 
surface with good sensitivity and speciﬁ  city for 
the discrimination of AP and CRC (9), these results 
remain to be validated in larger patient groups. 
Therefore, the current serum protein proﬁ  les can 
as yet not replace endoscopic screening. In addi-
tion, regarding the speciﬁ  city of apolipoprotein 
C-I for CRC, we must remark that a similar 
decrease of apolipoprotein C-I or protein peaks 
with similar mass has been described in several 
other types of cancer and benign disease (10; 18; 
19). Hence, its potential usefulness for CRC seems 
conﬁ  ned to follow-up of patients.
Besides serum, we have compared polyp and 
CRC tissue in order to elucidate any sequential 
protein expression differences occurring during the 
development from hyperplastic polyps to carci-
noma in situ and CRC. In addition we compared 
discriminating serum proteins with those in tissue. 
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Figure 3. Representative tissue protein proﬁ  les. M/z 6713 is shown 
in the box as an example of a protein differing between CON, 
AP and CRC.384
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We found a protein peak of 6.6 kDa, which might 
represent apolipoprotein C-I, in tissue samples. 
Contrary to serum, these peaks exhibited a higher 
abundance in CRC than in AP and CON. However, 
serum protein levels do not necessarily reﬂ  ect the 
processes occurring in tissue. For example, apoli-
poprotein A-I can be decreased in serum due to 
less synthesis in the liver, but increased in tissue 
due to local synthesis (10; 20). A gradual increase 
of the 6.6-kDa peak and others was obvious look-
ing only at the different histologic subtypes of 
polyps, indicating that these subtypes indeed reﬂ  ect 
the extent of transformation of these polyps. Also, 
a relationship between peak intensity and polyp 
size was observed for some peaks, which indicates 
that polyp size could be a surrogate measure for 
the extent of malignant transformation. Whether 
hyperplastic polyps are in fact pre-malignant stages 
of CRC, as is suggested by the hyperplastic 
polyposis syndrome (21), and not innocent polyps, 
remains to be established by direct comparison of 
hyperplastic polyp and normal tissue protein 
proﬁ  les. Normal tissue was not analysed in the 
current study, as we did not attempt to ﬁ  nd diag-
nostic tissue proteins, because of the limited utility 
of tissue as a matrix for screening purposes due to 
the need for colonoscopy.
Several reports have described the increase of 
α-defensin 1–3 levels in CRC tissue (22; 23). In 
the current study we also found peaks with masses 
corresponding to these proteins, namely m/z 3442, 
3375 and 3493. Only the ﬁ  rst peak was also found 
increased in CRC compared to AP and CON in our 
study. In the pair wise comparison of CON and 
CRC, we found m/z 3493 borderline signiﬁ  cantly 
increased in CRC (p = 0.019). The facts that we 
did not compare normal mucosa to CRC and used 
whole tumour tissue instead of microdissected 
tumour cells are likely the cause of the discrepan-
cies with published reports. Whereas others have 
also reported the presence of these peptides in 
serum and suggested their potential as serum mark-
ers (22; 23), we did not detect them in serum under 
the current binding conditions. The potential of the 
α-defensins as diagnostic biomarkers for CRC 
seems limited, as their serum levels are also 
increased in other cancers and several benign 
immunological conditions. Furthermore, our tissue 
protein proﬁ  ling results indicate that their expres-
sion is only increased in CRC and not yet in polyps, 
hampering their use for the identiﬁ  cation of polyps 
with malignant potential. Yet, as suggested 
previously, they may be useful as markers for CRC 
prognosis and monitoring (24). Unlike Melle et al. 
(25; 26) we did not observe a signiﬁ  cant expression 
difference between AP and CRC at 10.84 or 12.0 
kDa that could correspond to heat shock protein 
10 or calgizzarin. This may also be caused by the 
above-mentioned difference in tissue processing.
Concluding, we validated the decrease of 
apolipoprotein C-I serum levels in CRC in a large 
prospective study with SELDI-TOF MS. Yet, 
quantitative methods for apolipoprotein C-I 
measurement should be developed and used to 
establish reliable cut-off values for its clinical use. 
In addition, we found gradual changes in protein 
expression along the different stages of the 
adenoma-carcinoma sequence, which may help 
discern adenomatous polyps with malignant 
potential.
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